Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-27

Clinical Trial Update: Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

View source ↗

Summary

Clinical trial update on the effectiveness of Paritaprevir/ritonavir-ombitasvir +/- dasabuvir +/- ribavirin in chronic hepatitis C patients in Canada; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dasabuvir (dasabuvir)
  • Ribavirin (ribavirin)
  • paritaprevir/ritonavir-ombitasvir (paritaprevir/ritonavir-ombitasvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C | Status: COMPLETED | Results posted: 2019-03-27